Interní Med. 2006; 8(11): 513-514 [Interv Akut Kardiol. 2006;5(2):90-92]

Méně obvyklé nežádoucí účinky amiodaronu

MUDr. Tomáš Janota CSc, MUDr. Jan Malík, MUDr. Robert Holaj, MUDr. Jan Šimek
III. interní klinika VFN a 1. LF UK, Praha

Kazuistika popisuje průběh onemocnění pacienta s kumulací tří nežádoucích účinků amiodaronu. Na prvním místě to byl méně známý parkinsonský syndrom. Druhým nežádoucím účinkem byl bronchospazmus, který je také dosti vzácnou komplikací. Třetím nežádoucím účinkem bylo prodloužení QT intervalu, které je známým, ale někdy trochu opomíjeným nebezpečným důsledkem léčby amiodaronem. Kazuistika upozorňuje na rostoucí riziko výskytu nežádoucích účinků u nemocných v těžkém stavu a na význam znalosti i méně obvyklých nežádoucích účinků léčby.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janota T, Malík J, Holaj R, Šimek J. Méně obvyklé nežádoucí účinky amiodaronu. Interní Med. 2006;8(11):513-514.
Download citation

References

  1. Lombard M, Sarsfield P, Keogh JA. Adverse neurological response to amiodarone. Ir Med J. 1986; 79: 71-2. Go to PubMed...
  2. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25: 630-2. Go to original source... Go to PubMed...
  3. Dotti MT, Federico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233-234. Go to original source... Go to PubMed...
  4. Matsui A, Matsuo H, Takanaga H, Sasaki S, Maeda M, Sawada Y. Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J Pharmacol Exp Ther. 1998; 287: 725-32. Go to PubMed...
  5. Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994; 5:127-32. Go to original source... Go to PubMed...
  6. Imamura H, Kinoshita O, Maruyama K, Izawa A, Uchikawa SI, Kumazaki S, Takahashi W, Yokoseki O, Yazaki Y, Koizumi T, Kubo K. Two cases of bronchial asthma after treatment with amiodarone. Pacing Clin Electrophysiol. 2001; 24: 1563-5. Go to original source... Go to PubMed...
  7. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 1999; 84: 37R-45R. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.